Industry News (Hepatitis C)

Combination Therapy Advances to Phase III Trials

Published in Hepatitis Weekly, February 15th, 1999

Enzon, Inc., Piscataway, New Jersey, announced that Schering-Plough Corp. has initiated Phase III clinical trials for combination therapy of PEG-INTRON and Rebetol (ribavirin) for the treatment of hepatitis C.

PEG-INTRON is a modified form of Schering-Plough's INTRON A (interferon alfa-2b, recombinant) which was developed using Enzon's PEG technology to have longer-acting properties and the potential to offer an improved side-effect profile.

PEG-INTRON is also in Phase III clinical trials for two cancer indications, malignant melanoma and chronic myelogenous leukemia (CML), as well as early stage trials for various solid tumors.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1999-02-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry